Key result
Women with CAD show altered responses to standard treatments due to distinct pathophysiological and pharmacological differences.
This review highlights the critical need to recognize sex-specific differences in the pathophysiology of CAD and the pharmacokinetic/pharmacodynamic responses to cardiovascular therapies to optimize treatment for women.
Answers are grounded in this paper and cite their sources.
Supports sex-specific CAD management considerations; leaves open confirmation of outcome benefits in prospective trials.
More women than men die of coronary artery disease (CAD) each year. In women, cardiovascular disease can present atypically and may be caused by small vessel disease rather than by major epicardial coronary luminal narrowing. Women with CAD tend to have more diffuse disease, endothelial dysfunction, and microvascular disease than men. In those studies that have looked at sex differences in treatment response, sex-specific physiologic, pharmacokinetic, and pharmacodynamic differences appear to be the cause. Women have smaller hearts, higher heart rates, shorter cardiac cycle lengths, and longer QT intervals than men. CAD medical treatments such as antiplatelet agents, anticoagulants, beta-blockers, and antithrombin agents may have different effects in women and men. Only 30% of percutaneous coronary interventions are performed in women. Women are less likely than men to undergo diagnostic angiography and are more likely to experience delays in treatment.
No takes yet. Share an insight, caveat, or question.
A 2009 study conducted a review in Chronic Coronary Artery Disease. Cardiovascular treatments (pharmacological and invasive) vs. Men vs. Women (Sex differences) was evaluated. Women with coronary artery disease exhibit distinct pathophysiological, pharmacokinetic, and pharmacodynamic differences that alter their response to standard cardiovascular treatments compared to men.
Synapse has enriched 10 related papers. Consider them for comparative context: